Introduction
The concentration of cadmium (Cd) in urine is conventionally measured by graphite furnace atomic absorption spectroscopy (GF-AAS), and the detection-limit value is reported to be 0.5 mg L -1 . 1 Inductively coupled plasma-mass spectrometry (ICP-MS) can detect Cd at levels of nanograms per liter; 2 however, mass spectral interference by molybdenum oxide (MoO) generated in a hot plasma has been observed in both sediment analysis 3 and biological samples. 4, 5 Molybdenum (Mo) is an essential element for nutrition, and enters the human body primarily in the diet with an average dietary daily intake of approximately 100 mg day -1 . 6 Urinary Mo levels were reported to be 10 -120 mg L -1 in Europeans, 7 and 10 -200 mg L -1 in Japanese; 8 a geometric mean (GM) of 41.1 mg L -1 was reported in US adults. 6 In contrast, the average urinary Cd concentration in the normal population was reported to be 1.09 mg L -1 (<0.5 -22.8 mg L -1 ) in Japanese women 9 and 0.273 mg L -1 in US adults. 6 Thus, the urinary Mo concentration in the normal population is at least tens to hundreds of times higher than the Cd concentration.
In general, the determination of the concentrations of trace elements needs to take into account the influence of matrix effects, especially in biological and environmental samples. ICP-MS measurements are sensitive to: 1) chemical interference due to alterations in the ionization efficiency of the element of interest within the constituent matrix; 2) physical interference caused by variations in the sample transportation and nebulization at sample introduction into the plasma; and 3) spectral interference caused by isotopes of other elements and polyatomic species, all of which are isobaric with the element of interest. 10 Recently, Dynamic Reaction Cell (DRC) technology, an innovation in ICP-MS, has been successfully used to determine Cd levels in the presence of excess Mo. 11, 12 We examined the magnitude of the spectral interference caused by Mo and the efficacy of the DRC technique, and also managed to remove Mo from urine samples before an ICP-MS measurement using solidphase extraction (SPE) with a functional chelating resin. The commercially available NOBIAS PA-1 chelating resin that we used was a poly(hydroxy methacrylate)-based porous resin in which, according to the supplier, imino-diacetic acid and ethylenediamine triacetic acid groups are introduced as functional groups. NOBIAS PA-1 was successfully used for ICP-MS analysis of trace elements in seawater in the presence of abundant alkali and alkaline earth metal elements; 13, 14 this approach has also been used for the rapid and accurate determination of Pb in workers' urine, effectively removing alkali and alkaline earth metal elements. 15 
Experimental

Reagents and chemicals
A single-element, standard Cd solution for AAS (101.0 mg/L, Wako Pure Chemicals, Osaka, Japan) was diluted with 0.15 M nitric acid (HNO3) prepared from TAMAPURE AA-100 nitric acid (68%, Tama Chemicals, Kawasaki, Japan), and used for calibration and also as a standard-addition solution for Cd measurements. A rhodium (Rh) standard solution for AAS (1000 mg/L), used as an internal standard, and an Mo standard solution for AAS (1000 mg/L) were purchased from Wako Pure Chemicals (Osaka, Japan) and diluted with 0.15 M HNO3. Ultra-pure water for trace-element analysis was prepared using an Ultrapure Water Purification System (Milli-Q-ICP-MS, Millipore, Tokyo, Japan). 
Notes
Determination of Sub-ppb Cadmium in Urine by
Urine samples
Urine samples used in the experiment were collected from 55 healthy female Tokyo residents aged 24 -43 years (average age, 32.5 ± 4.3). 16 Urine voided in the morning was placed in a sealed plastic tube and stored at -80˚C in a freezer until being analyzed. This study was approved by the Institutional Review Board of National Cancer Center (Accession No. 12-6).
SPE of urine samples
SPE was performed with a functional chelating resin column (NOBIAS Chelate PA-1, Hitachi High Technology, Tokyo, Japan). Dry sorbent in an amount of 240 mg was packed into a syringe of diameter 12.5 mm, to a sorbent height of 6 mm. The chelating column was preconditioned as follows: 10 mL of acetone, followed by 15 mL of ultra-pure water, 5 mL of 3 M HNO3, 15 mL of ultra-pure water, and finally 5 mL of 0.1 M ammonium acetate (NH4COOCH3) (pH 8.6). Two milliliters of a defrosted urine sample were diluted with 10 mL of 0.2 M NH4COOCH3 (pH 8.6) and adjusted to 20 mL by the addition of ultra-pure water, and then loaded onto the preconditioned SPE chelating resin. After washing with 10 mL of ultra-pure water, the Cd chelated with this resin was eluted in sequence with 1 mL of 1 M HNO3 and 1 mL of ultra-pure water. This 2 mL of the eluate was mixed with 0.1 mL of Rh standard (5 mg L -1 ), and then measured by ICP-MS. The recovery of Cd was tested using Cd-spiked urine samples.
ICP-MS measurements
All ICP-MS measurements were performed with an Elan DRCII ICP-MS (PerkinElmer SCIEX, Concord, Ontario, Canada). Instrumental conditions were as follows: RF power, 1300 W; argon plasma gas flow, 15 L/min; auxiliary flow, 1.2 L/min; nebulizer flow, 1.0 L/min; a coaxial-type nebulizer was used; skimmer and sample cones were platinum; elemental Cd was measured at both m/z of 111 and 114, and these signals were corrected against an internal, standardized Rh signal at m/z 103.
DRC mode operation was additionally set as follows: oxygen (O2, >99.999%) as the reaction gas; the rejection parameter, q (RPq), of the DRC; the axial field voltage, and the flow rate of O2 were optimized and set at 0.75, 275 V and 2.0 mL/min, respectively.
Validation
The limit of detection (LOD) of a Cd standard solution and the method limit of quantification (MLOQ) of Cd in urine using SPE were calculated in accordance with the Japanese Industrial Standards (JIS) definition. 17 LOD was calculated based on 3-times the standard deviation (SD) of the results of 10 repeated runs using a blank solution. MLOQ was calculated by 14.1-times the SD of the ten SPE-processed blank solutions.
The accuracy of the method was assessed using a reference material, SRM 2670a (Toxic Elements in Urine), from the National Institute of Standard & Technology (NIST), Gaithersburg, MD, USA. To evaluate urinary Cd analysis, we have participated annually in the German External Quality Assessment Scheme (G-EQUAS) for the analysis of biological materials. Participating in this program in 2007, we analyzed four types of reference urine with certified Cd concentrations.
Results and Discussion
Reduction of interference
Chemical, physical and spectral interference can be reduced by sample dilution, but this approach leads to a trade-off involving a loss of sensitivity. Therefore, the standard-addition method is often employed to determine the amount of a target element in the matched matrix. However, this method does not quantify or compensate for spectral interference. The mass number selected is often interfered with by isobaric isotopes of other elements, and the analysis is further complicated when oxides and polyatomic species are taken into account. Since
114
Cd is interfered with by 114 Sn, though Sn is of low abundance, we chose to determine 111 Cd. The NIST SRM 2670a reference urine samples were diluted five times with ultra-pure water, and analyzed by the standard-addition method using ICP-MS; the Cd concentration obtained with measurements of 111 Cd was 0.125 ± 0.011 mg Cd L -1 (n = 5) against the certified value of 0.0591 ± 0.0034 mg Cd L -1 in low-level urine and 5.616 ± 0.0782 mg L -1 (n = 5) against 4.862 ± 0.084 mg L -1 of the certified value in high-level urine. These values were outside the range of the certified values. The higher values observed may have been caused by spectral interference of MoO (m/z 111), generated in the plasma, interfering with Cd isobars, because coexisting Mo concentrations in NIST SRM 2670a were found to be 17. 16 O, respectively. It is apparent that 0.1 -0.2% of the Mo atoms were converted to MoO and contributed to interference signals at m/z 111 and 114 when Cd was measured at these mass-to-charge ratios.
To remove the interference by MoO, DRC incorporated with ICP-MS was set up to convert MoO to MoO2 using oxygen as the reaction gas, as the higher mass of MoO2 would no longer interfere with the signals at m/z 111 and 114. of Cd. No interference with Cd by Mo was observed in the 111 Cd and 114 Cd measurements. This technique was then applied to the determination of Cd levels in NIST SRM 2760a urines. As can be seen in Table 1 , the number of significant digits was limited due to the lowered sensitivity with the use of DRC; for instance, only 20 CPS for 0.05 mg Cd L -1 . This finding was due to scattering and diminished transmittance of the concerned ion for collisions with the reaction gas, oxygen in the DRC. The ICP-MS instrument used has a function called an axial field voltage setup that additionally accelerates ions and increases the sensitivity. Although Chang et al. reported order-of-magnitude gains using this function, 11 we found that the gain was not high, being limited to a few multiples of ten percent improvement over the range, up to the maximum voltage of 450 V. In addition, the DRC approach resulted in a higher value of Cd in the NIST high-level reference urine with marked variation. These findings of low sensitivity and the variance with the standards were not consistent with the objectives of our study, along with general concerns about unwanted reactions between urine constituents and oxygen, and possible interference of such constituents with analytes. We discontinued the DRC approach (a subject for possible future investigation), and used an alternative approach, described below.
Recently, Murphy and Vocke reported that spectral interference, non-spectral interference and sample loading of the plasma can play a role in limiting the accuracy of Cd measurements by ICP-MS at low Cd concentration in biological samples, 2 in which case matrix separation becomes necessary. We have tried to locate an SPE sorbent to selectively remove Mo, but retain Cd in urine samples. Sakamoto et al. reported that a chelating resin, NOBIAS PA-1, retains Cd in the range of pH 4 -10, but only retains Mo at a pH range of 3 -7; 14 Mo retention tended to zero above pH 8. They also reported that the alkaline earth metal elements (Mg and Ca) were retained in this pH range. 14 We examined the influence of these elements on Cd signals in ICP-MS measurement using nitric solutions of 5 ppb Cd, spiked as 20 ppm Ca (4000 times the Cd level) and 10 ppm Mg (2000 times the Cd level), which are similar to the concentration levels of NIST SRM 2670a. The signal intensity for Cd was not altered by the coexistence of these elements.
In our sample preparation, as described in Experimental section, each 2 mL urine sample was diluted with 0.2 M NH4COOCH3 at pH 8.6, before loading onto the chelating resin, and the Cd on the sorbent was eluted by the strong acidity of 1 M HNO3. Subsequently, 2 mL of collected solution was analyzed by ICP-MS, and therefore no dilution was employed for the urine sample; this approach was useful in determining low levels of Cd. After SPE, the residual Mo concentration in the sample solution was found to be as low as 0.014 -2.521 mg L -1 over all urine samples in this study. This suggests that the spectral interference of Mo with Cd is only significant to the third decimal digit of the concentration (or less) in units of mg Cd L -1 , which met our criteria for low-level Cd determination.
Evaluation of the SPE-ICP-MS method
For Cd, the value obtained from a blank sample using SPE was 0.0069 ± 0.0009 mg L -1 (mean ± SD, n = 10). MLOQ of this analytical procedure was calculated as being 0.012 mg L -1 for Cd in urine. In practice, the concentrations in all samples were higher than this MLOQ level. The recovery of Cd from urine spiked at 0.0505 mg L -1 was 93.1 ± 10.2% (n = 5), and at 5.05 mg L -1 was 97.6 ± 2.1% (n = 5). The accuracy of the present analytical procedure was tested by analyzing NIST SRM 2670a (Toxic Elements in Urine), which has been certified for low concentrations of seven metals in urine and high concentrations of 10 metals in urine; both certifications include Cd. The Cd concentrations determined by the present SPE-ICP-MS method were within the allowable errors for certified values, as shown in Table 1 . In addition, in Table 2 we show the results of G-EQUAS-40 in 2007 for analysis of reference samples of human urine, which is certified for Cd.
When 55 urine samples were analyzed by this SPE-ICP-MS, the geometric mean (GM) of Cd concentrations was 0.856 ± 1.935 (range: 0.207 -3.695) mg L -1 . Figure 3 shows the relationship between the Cd and Mo concentrations in urine samples. The Mo concentration in Fig. 3 was determined by ICP-MS measurements with the standard-addition method without any SPE treatment, and the GM of Mo concentration was 153.9 ± 1.7 (range: 37.7 -475.1) mg L -1 . No correlation was found between the Cd and Mo concentrations when the SPE-ICP-MS measurement was used, in contrast to the findings without SPE where there was significant correlation. This finding clearly demonstrates that Mo is a major source of interference in the determination of low-level urinary Cd concentrations.
Conclusion
We found that Mo oxides generated in plasma interfered substantially with ICP-MS measurement of Cd. The DRC technique combined with the use of oxygen gas successfully reduced the interference attributable to Mo, but failed to provide accurate urinary Cd measurements owing to sensitivity tradeoffs. A new chelating method was then developed and applied to successfully minimize the amount of Mo in urine samples before the ICP-MS measurement. This approach successfully permitted the determination of Cd in urine at a lower threshold level of 0.05 mg L 
